Result of AGM

Life Science REIT PLC
23 May 2024
 


Life Science REIT plc

(the "Company")

 

LEI: 213800RG7JNX7K8F7525

 

23 May 2024

 

Annual General Meeting ("AGM") Results

The Company announces that at its Annual General Meeting held earlier today all the resolutions set out in the Notice of Annual General Meeting were passed. All resolutions were voted on by way of a poll.  The results of the poll for each resolution were as follows:

 

 

Resolution

 

 

 

 

 

 

For

Against

 

 

Votes Withheld

(No. of shares)

 

No. of shares

 

%

 

No. of shares

%

 

1.   To receive and approve the annual report and financial statements

 

 

247,928,546

 

99.99%

 

14,663

 

0.01%

 

26,709

 

2.   To receive and approve the Directors' remuneration report

247,684,045

 

99.97%

 

68,743

 

0.03%

 

217,130

 

3.   To approve the Company's dividend payment policy

 

247,966,918

 

99.99%

 

3,000

 

0.01%

 

0

 

4.   To re-elect Claire Boyle as a Director of the Company

 

229,246,645

 

95.31%

 

11,291,786

 

4.69%

 

7,431,487

 

5.   To re-elect Sally Ann Forsyth as a Director of the Company

 

217,454,934

 

94.13%

 

13,561,582

 

5.87%

 

16,953,402

 

6.   To re-elect Michael Taylor as a Director of the Company

 

238,575,348

 

99.18%

 

1,963,083

 

0.82%

 

7,431,487

 

7.   To re-elect Richard Howell as a Director of the Company

 

238,572,783

 

99.18%

 

1,965,648

 

0.82%

 

7,431,487

 

 

8.   To re-appoint Deloitte LLP as Auditor to the Company

 

247,897,047

 

 

99.97%

 

 

64,398

 

 

0.03%

 

 

8,473

 

 

 

9.   To authorise the Audit and Risk Committee to determine the remuneration of the Auditor to the Company

 

 

247,916,572

 

 

99.98%

 

 

53,346

 

 

0.02%

 

 

0

 

 

10.  To authorise the Directors to allot equity securities

 

222,777,035

 

89.84%

 

25,192,883

 

10.16%

 

0

 

 

11.  To authorise the Directors to disapply pre-emption rights*

 

232,274,638

 

 

93.68%

 

 

15,668,571

 

 

6.32%

 

 

26,709

 

 

 

12.  To authorise the Directors to disapply pre-emption rights for the purposes of financing an acquisition or other capital investment*

 

231,970,086

 

 

93.58%

 

 

15,920,407

 

 

6.42%

 

 

79,425

 

 

 

13.  To approve the purchase of the Company's own shares*

 

 

 

236,334,255

 

 

 

95.31%

 

11,635,663

 

4.69%

 

0

 

14.  That a general meeting, other than an AGM, may be called on not less than 14 clear days' notice*

244,386,609

 

 

98.56%

 

 

3,580,744

 

 

1.44%

 

 

2,565

 

 

 

*special resolution

 

NOTES:

 


1.

All resolutions were passed.

 

2.

 

Percentages have been rounded to two decimal places.

3.

Proxy appointments which gave discretion to the Chair of the AGM have been included in the "For" total for the appropriate resolution.

 

4.

Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.

 

5.

A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.

 

6.

The number of shares in issue at 6:00 pm. on 21 May 2024 was 350,000,000 ordinary shares, carrying one vote each, and at that time, the Company did not hold any shares in treasury.

 

7.

The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at https://lifesciencereit.co.uk/investors/shareholder-information/

 

 

Enquiries:

Link Company Matters Limited - Company Secretary

 

labs_cosec@linkgroup.co.uk

 

 

 

Ironstone Asset Management - Investment Adviser

 

Simon Farnsworth/ Joanna Waddingham

via Buchanan below

 

 

Panmure Gordon - Joint Corporate Broker

+44 20 7886 2500

Alex Collins / Tom Scrivens


 

 

Jefferies International Limited - Joint Corporate Broker

+44 20 7029 8000

Tom Yeadon 

  

 

G10 Capital Limited - AIFM

+44 20 7397 5450

Verity Morgan-Jones / Maria Baldwin


 

Buchanan - Financial PR

 

+44 20 7466 5000

Mark Court / Henry Wilson / Verity Parker          


LifeSciencereit@buchanan.uk.com


 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings